Peptide · Fact sheet

Humanin

Also known as HN · MT-RNR2 peptide · S14G-humanin (experimental analog)

Humanin is a naturally occurring mitochondrial-derived peptide studied in cell survival, neurodegeneration, metabolism, and aging. No humanin drug product is FDA approved, and there is no convincing clinical trial evidence that taking a humanin product improves cognition or extends healthy life.

Preclinical researchMostly animal or lab research

What is Humanin?

Humanin is a short peptide encoded within the mitochondrial MT-RNR2 region and involved in stress-response and cell-survival signaling.

Researchers also study more potent synthetic analogs such as S14G-humanin; results from an analog, a cell experiment, or a blood-level association do not prove a treatment effect from native humanin.

Benefits & claims

Cell and animal models report neuroprotective, metabolic, retinal, cardiovascular, and anti-apoptotic signals.

Human genetics and biomarker studies link Humanin biology with cognitive aging or disease, but those associations are not trials of a humanin medicine.

What the evidence supports

  • Laboratory and animal studies report protection from selected toxic or metabolic stresses.
  • A human genetic association study linked a variant associated with lower circulating humanin to cognitive aging, but did not test humanin treatment.
Research areas
  • Neuroprotection in laboratory and animal models
  • Cognitive aging associations
  • Metabolic and insulin-signaling biology
  • Retinal and cardiovascular cell protection
  • Muscle-atrophy mechanisms in cultured human cells
  • Neurodegenerative-disease mechanisms
  • Mitochondrial and metabolic stress
  • Healthy-aging and muscle-protection research

Dosage & frequency

No established human regimen

Humanin and related analogs remain predominantly preclinical. No established human treatment dose or frequency is supported by reviewed evidence.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Formulation differences

  • Humanin analogs such as HNG are different molecules; animal results cannot establish a shared human dose.

Interactions & precautions

  • No established human drug-interaction profile exists for native humanin or its preclinical analogs.

What is still unresolved

  • Human formulation, exposure, clinical efficacy, repeated-use safety, and interactions remain unestablished.

Side effects & risks

  • A reliable human treatment safety profile has not been established.
  • Analog identity, exposure, immune reactions, off-target signaling, and long-term effects remain poorly defined.
  • Products sold outside an approved application add quality, purity, sterility, strength, and labeling uncertainty.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Mostly animal or lab research

The treatment literature is dominated by cell and animal studies. Human studies are primarily observational, genetic, or biomarker research and cannot show that administering humanin improves outcomes.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Mixed account · personal report

More energy, but difficulty sleeping

A commenter who described Friedreich’s ataxia reported substantially more energy after Humanin, followed by difficulty sleeping that night.

Reported use in this account

Product
Product described as Humanin
Amount
About 50 mcg, as reported
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Not specified clearly

Other exposures described: Other growth-hormone peptides; identities and timing not stated

The account also discusses other peptides. Diagnosis, product identity and cellular energy production were not verified; the author’s mechanism and handling claims are not evidence.

Read the original account

Approval status

No humanin or humanin-analog product is FDA approved. Human therapeutic development has not produced a mature clinical program establishing benefit for cognition, neurodegeneration, metabolism, or aging.

Preclinical and observational research

Humanin research is dominated by cell, animal, genetic, and biomarker studies. The page references do not show a mature human treatment program or FDA approval.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Whether humanin or an analog can improve any clinical outcome in people
  • Which molecule, formulation, and target population would be appropriate for trials
  • Short- and long-term safety
  • Whether observational links with aging or cognition are causal

Summary

Humanin remains a preclinical research subject, without proven cognitive, muscle or longevity benefits in people.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. pubmedHumanin and cognitive aging study

    Cell, animal, and human genetic-association findings; not a human treatment trial.

  2. pubmedHumanin lifespan and healthspan research

    Multi-species preclinical and observational study that does not establish a human longevity treatment.

  3. pubmedHumanin retinal-cell protection study

    Laboratory study in retinal pigment epithelial cells supporting preclinical mechanisms.

  4. pubmedHumanin and MOTS-c in cultured human muscle cells

    Laboratory study in human muscle cells, not a clinical trial in people.

How we assess sources · Suggest a correction